Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR01394
|
|||||
Drug Name |
Cefditoren
|
|||||
Synonyms |
Cefditoren [USAN:INN]; Meiact (TN); Spectracef (TN); (+)-(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-3-((Z)-2-(4-methyl-5-thiazolyl)vinyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-methyloxime); (6R-(3(Z),6alpha,7beta(Z)))-7-((2-Amino-4-thiazolyl)(methoxyimino)acetyl)amino-3-(2-(4-methyl-5-thiazolyl)ethenyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Acute bacterial exacerbation of chronic bronchitis [ICD11: CA20.1] | Approved | [1] | |||
Therapeutic Class |
Antibiotics
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C19H18N6O5S3
|
|||||
Canonical SMILES |
CC1=C(SC=N1)C=CC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O
|
|||||
InChI |
InChI=1S/C19H18N6O5S3/c1-8-11(33-7-21-8)4-3-9-5-31-17-13(16(27)25(17)14(9)18(28)29)23-15(26)12(24-30-2)10-6-32-19(20)22-10/h3-4,6-7,13,17H,5H2,1-2H3,(H2,20,22)(H,23,26)(H,28,29)/b4-3-,24-12-/t13-,17-/m1/s1
|
|||||
InChIKey |
KMIPKYQIOVAHOP-YLGJWRNMSA-N
|
|||||
CAS Number |
CAS 104145-95-1
|
|||||
Pharmaceutical Properties | Molecular Weight | 506.6 | Topological Polar Surface Area | 242 | ||
Heavy Atom Count | 33 | Rotatable Bond Count | 7 | |||
Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 12 | |||
XLogP |
0.7
|
|||||
PubChem CID | ||||||
PubChem SID | ||||||
ChEBI ID |
CHEBI:59343
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [2] | |
References | ||||||
1 | Cefditoren was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.